eif4ebp3l Antibody

What is eIF4EBP3L and how does it differ from other eIF4EBP family members?

eIF4EBP3L (eukaryotic initiation factor 4E-binding protein 3-like) is a member of the eIF4E-binding protein family that functions as a translational repressor. Unlike its family members eIF4EBP1 and eIF4EBP2, which are widely expressed in head and neural tissues, eIF4EBP3L shows a tissue-specific expression pattern predominantly in muscle tissue, somites, eye, and branchial arch regions in vertebrate models like zebrafish . The standard eIF4EBP3 (without the "L") shows yet another distinct expression pattern, being most abundant in pancreatic tissue .

The functional significance of eIF4EBP3L relates to its role as a gatekeeper of TORC1 (Target of Rapamycin Complex 1) in activity-dependent regulation, particularly in muscle tissue. Research has shown that muscle inactivity increases eIF4EBP3L mRNA levels approximately 2-fold, specifically in muscle tissues, suggesting a specialized regulatory function in response to activity changes . This activity-dependent regulation appears to be specific to eIF4EBP3L, as similar dramatic changes are not observed with other family members under the same conditions.

What are the key biological functions of eIF4EBP3L that researchers investigate using antibodies?

Researchers primarily use eIF4EBP3L antibodies to investigate translational control mechanisms in muscle development and activity-dependent signaling pathways. Key biological functions under investigation include:

• Regulation of protein synthesis in response to muscle activity changes

• Interaction with the TORC1 signaling pathway, where eIF4EBP3L appears to function as a regulatory gatekeeper

• Tissue-specific translational control, particularly in muscle, somite, eye, and branchial arch regions

• Developmental roles in tissue formation where eIF4EBP3L is highly expressed

Experimental evidence shows that when muscle activity is suppressed, either through chemical means (MS222 exposure) or in genetic models of muscle inactivity (chrnd sb13 mutant), eIF4EBP3L mRNA levels increase significantly (2-2.5 fold) . This suggests a potential role in homeostatic regulation of protein synthesis during periods of altered muscle activity. Antibodies against eIF4EBP3L enable researchers to detect changes in protein levels, phosphorylation status, and protein-protein interactions that are central to understanding these regulatory mechanisms.

What criteria should be used when selecting an antibody for eIF4EBP3L detection?

When selecting an antibody for eIF4EBP3L detection, researchers should consider several critical factors to ensure experimental success:

Specificity is paramount given the high sequence similarity between eIF4EBP family members. Researchers should prioritize antibodies validated for specificity against eIF4EBP3L versus other family members (eIF4EBP1, eIF4EBP2, and standard eIF4EBP3) . Verification of antibody specificity typically requires Western blot analysis showing distinct bands at the expected molecular weight (approximately 10-12 kDa for eIF4EBP family members) and lack of cross-reactivity with other family proteins.

Application compatibility is another essential criterion, as different experimental techniques require antibodies with specific characteristics. For Western blotting, antibodies should recognize denatured protein epitopes, while techniques like immunohistochemistry (IHC) or immunofluorescence (IF) require antibodies recognizing native protein conformations . Based on available commercial antibodies for eIF4EBP family members, researchers should verify that their selected antibody has been validated for their specific application, whether Western blot, ELISA, IHC, or immunocytochemistry (ICC) .

Species reactivity must be considered based on the model organism used in the research. Due to the evolutionary conservation of eIF4EBP family proteins, antibodies may exhibit cross-species reactivity, but this should be experimentally verified rather than assumed . The search results indicate that while antibodies exist for human eIF4EBP3, specific validation for eIF4EBP3L in other species may be limited.

How should researchers validate the specificity of an eIF4EBP3L antibody?

Validating an eIF4EBP3L antibody's specificity requires a multi-faceted approach:

Genetic validation represents the gold standard approach and involves testing the antibody in tissues or cells with genetic manipulation of eIF4EBP3L expression. Researchers should demonstrate antibody signal reduction in knockout or knockdown models (using siRNA or morpholinos) and signal increase in overexpression models . For instance, research has shown that morpholino knockdown of eIF4EBP3L (BP3LMO1) reduced eIF4EBP3L mRNA by approximately 80% as verified by qPCR . An effective antibody should show corresponding reduction in protein signal.

Peptide competition assays provide another validation method where the specific peptide used to generate the antibody is pre-incubated with the antibody before application to the sample. Disappearance of the signal indicates specificity for the target epitope. This is particularly important when new antibodies against eIF4EBP3L are developed.

Cross-reactivity testing with other eIF4EBP family members is essential given their structural similarity. Researchers should test the antibody against purified recombinant eIF4EBP1, eIF4EBP2, eIF4EBP3, and eIF4EBP3L proteins to demonstrate specific detection of eIF4EBP3L without cross-reactivity to other family members .

Multiple antibody validation involves using two or more antibodies raised against different epitopes of eIF4EBP3L. Concordant results from different antibodies significantly increase confidence in specificity. As noted in the search results, "In the absence of specific antibody against eIF4EBP3L, we verified the efficacy of BP3LMO1 by qPCR" , highlighting the current challenges in eIF4EBP3L antibody specificity.

What are the optimal conditions for Western blot detection of eIF4EBP3L?

Optimizing Western blot detection of eIF4EBP3L requires attention to several critical parameters:

Sample preparation is crucial for accurate detection. Researchers should use fresh tissue or cells, with rapid extraction in the presence of phosphatase inhibitors (sodium fluoride, sodium orthovanadate) and protease inhibitors to preserve the native state and phosphorylation status of eIF4EBP3L. Given eIF4EBP3L's tissue-specific expression, muscle tissue samples yield the highest detection levels, while pancreatic tissue should be used for standard eIF4EBP3 .

Protein separation requires special consideration due to eIF4EBP3L's relatively small size (approximately 10-12 kDa). Higher percentage polyacrylamide gels (15-18%) are recommended for optimal resolution of these small proteins. Researchers should include appropriate molecular weight markers that cover the 10-15 kDa range for accurate size determination.

Transfer conditions should be optimized for small proteins, typically using reduced methanol concentration (10% instead of 20%) and lower current to prevent small proteins from transferring through the membrane. PVDF membranes with 0.2 μm pore size (rather than standard 0.45 μm) are recommended for capturing small proteins like eIF4EBP3L.

Antibody dilution and incubation require empirical optimization, but based on typical protocols for other eIF4EBP family members, initial testing could begin with primary antibody dilutions between 1:500 to 1:2000, with overnight incubation at 4°C . Secondary antibody selection should match the host species of the primary antibody and be used at dilutions of 1:5000 to 1:10000.

Detection systems with enhanced sensitivity, such as chemiluminescence or fluorescence-based methods, are recommended due to potentially low abundance of eIF4EBP3L in some tissues. Positive controls (tissues known to express eIF4EBP3L) and negative controls (tissues known not to express eIF4EBP3L) should be included in each experiment.

How can researchers effectively use eIF4EBP3L antibodies for immunohistochemistry and immunofluorescence?

Effective immunohistochemistry and immunofluorescence with eIF4EBP3L antibodies require specialized protocols:

Tissue fixation methods significantly impact antibody performance. For eIF4EBP proteins, 4% paraformaldehyde fixation with careful optimization of fixation time (typically 24-48 hours for tissues, 10-20 minutes for cells) is recommended. Over-fixation can mask epitopes and reduce antibody binding, particularly for small proteins like eIF4EBP3L.

Antigen retrieval becomes critical when working with fixed tissues. Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) should be tested to determine optimal conditions for eIF4EBP3L detection. The specific buffer and conditions may need to be empirically determined for each antibody and tissue type.

Antibody concentration for IHC/IF typically differs from Western blotting, with higher concentrations often required (1:50 to 1:200 dilutions may be appropriate starting points). Extended primary antibody incubation (overnight at 4°C) generally improves specific signal detection.

Signal amplification systems such as tyramide signal amplification (TSA) or polymer-based detection systems can significantly enhance sensitivity for detecting low-abundance proteins like eIF4EBP3L in certain tissues. These methods may be particularly useful when studying tissues with lower expression levels.

Dual labeling with markers for specific cell types or subcellular compartments can provide valuable information about eIF4EBP3L localization and function. Based on its role in translational control, co-localization with ribosomal markers, stress granule components, or other translation factors may be informative.

What approaches can be used to study eIF4EBP3L phosphorylation status?

Studying eIF4EBP3L phosphorylation status is crucial for understanding its activity since, like other eIF4EBP family members, its function is regulated by phosphorylation:

Phospho-specific antibodies development and validation represent the most direct approach. While phospho-specific antibodies exist for the eIF4EBP family that may detect eIF4EBP3L phosphorylation at conserved sites like T45 , researchers should validate these for specificity to eIF4EBP3L. The search results mention "Anti-eIF4EBP1 + eIF4EBP2 + eIF4EBP3 (phospho T45) antibody [EPR2169Y]" , suggesting cross-reactivity that may extend to eIF4EBP3L if the phosphorylation site is conserved.

Phos-tag SDS-PAGE represents an alternative approach where phosphorylated proteins migrate slower than their non-phosphorylated counterparts, allowing visualization of different phosphorylation states without requiring phospho-specific antibodies. This technique is particularly valuable for detecting multiple phosphorylation states simultaneously.

Mass spectrometry offers the most comprehensive analysis of phosphorylation sites. Immunoprecipitation of eIF4EBP3L followed by mass spectrometry can identify specific phosphorylation sites and their relative abundance under different experimental conditions. This approach requires antibodies suitable for immunoprecipitation of the native protein.

Lambda phosphatase treatment of protein samples before Western blotting serves as a control to confirm that band shifts are due to phosphorylation. Treatment should collapse multiple bands to a single band representing the non-phosphorylated form if the protein exists in multiple phosphorylation states.

Kinase inhibitor studies using specific inhibitors of TORC1 (rapamycin) or other kinases in the pathway can provide insights into the regulation of eIF4EBP3L phosphorylation. Changes in phosphorylation status can be monitored by Western blotting following treatment.

How can researchers overcome cross-reactivity challenges when using eIF4EBP3L antibodies?

Cross-reactivity presents a significant challenge when working with eIF4EBP3L antibodies due to sequence similarity with other family members. Several approaches can help overcome this limitation:

Pre-absorption techniques involve incubating the antibody with recombinant proteins of other eIF4EBP family members before application to samples. This can reduce cross-reactivity by blocking antibody binding sites that recognize shared epitopes. Researchers should generate a dilution series of the competing protein to determine optimal pre-absorption conditions.

Knockout/knockdown controls provide the most definitive validation of antibody specificity. When available, tissues or cells with genetic ablation of eIF4EBP3L should be used as negative controls . Similarly, samples with verified eIF4EBP3L overexpression serve as positive controls. In cases where genetic models are unavailable, morpholino knockdown approaches have been shown to achieve approximately 80% reduction in eIF4EBP3L expression .

Alternative detection methods can bypass antibody specificity issues. RNA-based methods like qPCR or in situ hybridization can verify expression patterns when antibody specificity is questionable . While these methods detect mRNA rather than protein, they often provide complementary information about expression patterns.

Tissue-specific analysis leverages the differential expression patterns of eIF4EBP family members. Examining muscle tissue, where eIF4EBP3L is predominantly expressed, versus neural tissue, where eIF4EBP1 and eIF4EBP2 predominate, can help distinguish signals . Careful experimental design that includes tissues with known expression profiles of each family member enables better interpretation of results.

What strategies should be employed when typical antibody detection methods fail for eIF4EBP3L?

When standard antibody detection methods fail for eIF4EBP3L, researchers can employ alternative strategies:

Epitope-tagged constructs offer a reliable alternative where a known epitope tag (FLAG, HA, GFP) is fused to eIF4EBP3L for expression in cells or animal models. Well-validated commercial antibodies against these tags provide highly specific detection. This approach is particularly useful for overexpression studies and protein-protein interaction analyses.

Custom antibody development may be necessary when commercial antibodies prove inadequate. Selecting unique peptide sequences specific to eIF4EBP3L rather than conserved regions shared with other family members is critical. Biophysics-informed computational models, as described in search result , can help design highly specific antibodies: "Our biophysics-informed model is trained on a set of experimentally selected antibodies and associates to each potential ligand a distinct binding mode, which enables the prediction and generation of specific variants beyond those observed in the experiments" .

Mass spectrometry-based proteomics provides an antibody-independent approach to detecting and quantifying eIF4EBP3L. Targeted approaches like selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) can quantify specific peptides unique to eIF4EBP3L even in complex samples.

Bioinformatic approaches to predict cross-reactivity can guide antibody selection and experimental design. Sequence alignment of eIF4EBP family members helps identify regions of high similarity where cross-reactivity is likely and regions unique to eIF4EBP3L that might serve as better epitopes for specific antibody generation .

How can researchers accurately interpret eIF4EBP3L antibody signals in complex tissue samples?

Interpreting eIF4EBP3L antibody signals in complex samples requires rigorous controls and complementary approaches:

Multiple antibody validation involves using different antibodies targeting distinct epitopes of eIF4EBP3L. Concordant results from different antibodies significantly increase confidence in the specificity of the signal. This approach helps distinguish true eIF4EBP3L signal from cross-reactivity artifacts.

Correlation with mRNA expression provides supporting evidence for protein detection. Technologies like qPCR or in situ hybridization can verify eIF4EBP3L expression patterns independently of antibody-based methods . When protein and mRNA detection methods show congruent tissue distribution and expression changes, confidence in the results increases substantially.

Comparative analysis across experimental conditions known to regulate eIF4EBP3L adds another validation layer. For example, muscle inactivity (through MS222 exposure or in chrnd sb13 mutant models) increases eIF4EBP3L mRNA levels approximately 2-2.5 fold . If antibody signals show corresponding increases, this supports signal specificity.

Single-cell analysis techniques can resolve cell-specific expression patterns that might be obscured in whole-tissue samples. Techniques like imaging mass cytometry, multiplexed ion beam imaging, or single-cell Western blotting allow for more precise characterization of eIF4EBP3L expression at the cellular level.

How can researchers study the interaction between eIF4EBP3L and TORC1 signaling pathways?

Investigating the interaction between eIF4EBP3L and TORC1 signaling requires specialized approaches:

Co-immunoprecipitation experiments represent a fundamental approach for detecting protein-protein interactions. Using antibodies against eIF4EBP3L to immunoprecipitate protein complexes, followed by Western blotting for TORC1 components (mTOR, Raptor, etc.), can reveal direct or indirect interactions. Reciprocal experiments using antibodies against TORC1 components to pull down eIF4EBP3L provide additional validation.

Pharmacological manipulation of the TORC1 pathway using inhibitors like rapamycin or activators like amino acids can reveal functional relationships. If eIF4EBP3L truly functions as a "gatekeeper of TORC1 in activity-dependent regulation" , its phosphorylation status, localization, or abundance should change in response to TORC1 pathway modulation.

Proximity ligation assays (PLA) offer a powerful technique for visualizing protein-protein interactions in situ. This technique can detect when two proteins are within 40 nm of each other, providing evidence for interaction within intact cells or tissues without requiring protein extraction that might disrupt native complexes.

Genetic epistasis experiments in appropriate model systems can establish the functional relationship between eIF4EBP3L and TORC1. By manipulating eIF4EBP3L levels (overexpression or knockdown) and observing effects on TORC1 activity (often measured by phosphorylation of downstream targets like S6K), researchers can determine whether eIF4EBP3L functions upstream, downstream, or in parallel to TORC1.

ChIP-sequencing studies may be valuable if eIF4EBP3L is regulated at the transcriptional level by components of the TORC1 pathway. The search results mention the use of ChIP assays with anti-parafibromin, anti-Leo1, and anti-Paf1 antibodies to examine binding to the eIF4EBP3 promoter region , suggesting that similar approaches might be valuable for studying eIF4EBP3L transcriptional regulation.

What approaches are recommended for studying tissue-specific functions of eIF4EBP3L in muscle?

Studying the tissue-specific functions of eIF4EBP3L in muscle requires specialized experimental approaches:

Tissue-specific genetic manipulation using Cre-Lox systems, muscle-specific promoters, or other conditional expression systems allows precise control of eIF4EBP3L expression specifically in muscle tissues. This approach helps distinguish autonomous effects in muscle from secondary effects mediated by other tissues.

Activity-dependent regulation studies leverage the finding that eIF4EBP3L expression responds to muscle activity changes . Experimental paradigms that alter muscle activity, such as denervation, electrical stimulation, exercise, or immobilization, can reveal the physiological roles of eIF4EBP3L in activity-dependent muscle adaptation.

Translational profiling techniques like polysome profiling or ribosome profiling can directly assess eIF4EBP3L's impact on translation. Since eIF4EBP family members function as translational repressors, measuring translation rates of specific mRNAs in the presence or absence of eIF4EBP3L manipulation provides insights into its functional targets.

Ex vivo muscle preparation models allow controlled experimental conditions while maintaining tissue architecture. Isolated muscle preparations can be treated with compounds affecting TORC1 signaling while simultaneously monitoring contractile properties and molecular signaling, including eIF4EBP3L phosphorylation or expression.

Comparative analysis across models with distinct muscle activity patterns can provide insights without requiring experimental manipulation. For example, comparing eIF4EBP3L expression and phosphorylation in predominantly fast-twitch versus slow-twitch muscles, or in muscles from sedentary versus exercised animals, can reveal physiologically relevant differences in eIF4EBP3L function.

How can computational modeling and bioinformatics enhance eIF4EBP3L antibody design and research?

Computational approaches offer powerful enhancements to traditional antibody development and research strategies:

Biophysics-informed antibody design represents a cutting-edge approach described in the search results: "Our approach involves the identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not" . These computational models can predict antibody-epitope interactions and guide the design of highly specific antibodies that discriminate between eIF4EBP3L and other family members.

Epitope prediction algorithms analyze protein sequences to identify regions likely to be surface-exposed and immunogenic. For eIF4EBP3L, focusing on regions with low sequence conservation among family members increases the likelihood of generating specific antibodies. These algorithms can prioritize candidate epitopes before experimental validation.

Cross-reactivity prediction tools assess sequence and structural similarity between proteins to anticipate potential cross-reactivity. As described in the search results: "Using data from phage display experiments, we show that the model successfully disentangles these modes, even when they are associated with chemically very similar ligands" . Such tools can help researchers select antibodies with minimal cross-reactivity to other eIF4EBP family members.

Protein structure modeling, when crystal structures are unavailable, can predict the three-dimensional conformation of eIF4EBP3L. These models help identify surface-exposed regions accessible to antibodies and predict conformational changes upon phosphorylation that might affect antibody binding.

Machine learning approaches that integrate experimental antibody selection data can improve prediction accuracy: "This approach involves the identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not" . These models learn patterns from successful antibodies to design new ones with enhanced specificity and affinity.

How should experiments be designed to distinguish between eIF4EBP3L and other eIF4EBP family members?

Designing experiments to differentiate between eIF4EBP family members requires careful consideration of their distinct expression patterns and regulatory mechanisms:

Tissue selection strategy leverages the differential expression patterns of eIF4EBP family members. As indicated in the search results, eIF4EBP1 and eIF4EBP2 are widely expressed in head and neural tissues, standard eIF4EBP3 is abundant in pancreas, while eIF4EBP3L is predominantly expressed in muscle tissue, somites, eye, and branchial arch regions . Comparing signals across these tissues helps distinguish between family members.

Activity-dependent regulation analysis takes advantage of the finding that muscle inactivity specifically increases eIF4EBP3L mRNA levels (2-2.5 fold) without similarly affecting eIF4EBP1 in genetic models of muscle inactivity (chrnd sb13 mutant) . This differential regulation provides a functional readout to distinguish eIF4EBP3L from other family members.

Family-wide expression analysis using multiple antibodies (each specific to a different family member) applied to the same samples enables direct comparison of expression patterns. This comprehensive approach reveals the relative abundance and distribution of each family member across tissues and conditions.

Paralog-specific knockdown using siRNA or morpholinos targeted to unique regions of each family member provides genetic validation of antibody specificity. The search results mention that morpholino knockdown achieved approximately 80% reduction in eIF4EBP3L mRNA . Antibody signals should decrease only when the targeted family member is knocked down if the antibody is truly specific.

The following table summarizes key differences between eIF4EBP family members based on the search results, which can guide experimental design:

What methodological approaches are recommended when investigating eIF4EBP3L in developmental contexts?

Investigating eIF4EBP3L in developmental contexts requires specialized methods suitable for embryonic and developing tissues:

Developmental time-course analysis involving sample collection at multiple developmental stages enables tracking of eIF4EBP3L expression changes during critical developmental windows. Based on its expression in somites, eye, and branchial arch regions , these tissues should be examined closely during formation and differentiation stages.

In situ hybridization provides spatial information about mRNA expression patterns in intact tissues, which is particularly valuable in developmental studies. This technique can reveal tissue-specific expression patterns of eIF4EBP3L during development before antibodies are applied, helping guide subsequent protein-level analyses.

Lineage-specific markers co-labeling with eIF4EBP3L helps identify the specific cell types expressing the protein during development. Given its expression in muscle, pairing eIF4EBP3L detection with markers for different stages of myogenic lineage (Pax7, MyoD, myogenin, etc.) can reveal when during muscle development eIF4EBP3L becomes expressed.

Genetic manipulation in developmental models, such as morpholino knockdown in zebrafish embryos (as mentioned in the search results with BP3LMO1 achieving 80% reduction in eIF4EBP3L mRNA ), allows functional assessment of eIF4EBP3L's role in development. Phenotypic analysis following knockdown can reveal developmental processes requiring eIF4EBP3L function.

Ex vivo developmental assays using explanted tissues or embryonic stem cell differentiation models provide controlled environments to study eIF4EBP3L's role in specific developmental processes. For example, muscle differentiation models (using C2C12 cells or primary myoblasts) can reveal eIF4EBP3L's role in myogenesis under defined conditions.